Join
Live feed
·
PRReleasevia Quantisnow
Lumos Pharma Inc. logo

Lumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD Met All Primary and Secondary Endpoints

ByQuantisnow·Wall Street's wire, on your screen.
LUMO· Lumos Pharma Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track LUMO (Lumos Pharma Inc.) and more on Quantisnow.